Consultant Sushrut ENT Hospital and Dr. Khan's ENT Research Center, Talegaon Dabhade, India.
Am J Otolaryngol. 2021 Mar-Apr;42(2):102880. doi: 10.1016/j.amjoto.2020.102880. Epub 2021 Jan 4.
STUDY DESIGN: Observational study.
Secondary care ENT Centre.
All patients attending the hospital for office ENT consultations from 15th April 2020 to 15th September 2020 were included in the study. A total of 6692 office patients were evaluated for feasibility, usability and tolerability of the 0.5% PVP-I gargles and nasal drops.
Overall practicability of using 0.5% PVP-I gargles and nasal drops at office level was assessed in terms of feasibility and usability. Feasibility and usability was considered in terms of the ease of the dispensing method of the 0.5% PVP-I gargles and nasal drops by the health care workers to the patients prior to ENT examination. Tolerance was assessed in terms of altered taste, staining of teeth or nasal skin or irritation in the nose. None reported any serious reactions or adverse effects following use of 0.5% PVP-I.
The study reports the successful feasibility and usability of 0.5% PVP-I gargles and nasal drops and bears the potential to provide benefits in preventing transmission from the patients to the health care workers and vice versa.
研究设计：观察性研究。
二级保健耳鼻喉中心。
从 2020 年 4 月 15 日至 2020 年 9 月 15 日，所有在医院就诊的耳鼻喉科门诊患者均纳入本研究。共有 6692 名门诊患者评估了 0.5%PVP-I 漱口液和滴鼻剂的可行性、可用性和耐受性。
总体而言，在门诊环境下使用 0.5%PVP-I 漱口液和滴鼻剂的实用性是根据可行性和可用性来评估的。可行性和可用性是根据医护人员在耳鼻喉科检查前向患者分配 0.5%PVP-I 漱口液和滴鼻剂的简便程度来考虑的。耐受性是根据味觉改变、牙齿或鼻腔皮肤染色或鼻腔刺激来评估的。无人报告使用 0.5%PVP-I 后出现任何严重反应或不良反应。
本研究报告了 0.5%PVP-I 漱口液和滴鼻剂的成功可行性和可用性，并具有潜在的益处，可以防止患者向医护人员传播，反之亦然。
4 级。
